Clinical Trials Logo

Ischemic Stroke clinical trials

View clinical trials related to Ischemic Stroke.

Filter by:

NCT ID: NCT03897478 Recruiting - Stroke Clinical Trials

Biomarkers of Acute Stroke in Clinic

BASIC
Start date: April 1, 2019
Phase:
Study type: Observational

The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic strokes, when hemorrhagic stroke is ruled out, as defined by TOAST classification of subtypes of acute ischemic stroke. Aim 2: In cases of ischemic strokes of unknown or "cryptogenic" etiology, determine the ability of biomarker blood tests to predict etiology between cardioembolic and large artery atherosclerotic.

NCT ID: NCT03892226 Active, not recruiting - Stroke, Ischemic Clinical Trials

Cardiomyocyte Injury Following Acute Ischemic Stroke

CORONA-IS
Start date: April 1, 2019
Phase:
Study type: Observational

The primary goal of the CORONA-IS study is to characterize stroke-associated acute myocardial injury (elevated hs-cardiac troponin) using different diagnostic examinations in order get a better understanding of it's underlying pathomechanisms.

NCT ID: NCT03890380 Terminated - Ischemic Stroke Clinical Trials

Safety and Performance Evaluation of the Magneto Wire

Start date: December 17, 2018
Phase: N/A
Study type: Interventional

A prospective, open label single arm feasibility study to evaluate the safety and performance of the Magneto Wire in patients diagnosed with acute ischemic stroke and planned for thrombectomy procedure.

NCT ID: NCT03889249 Completed - Stroke, Acute Clinical Trials

Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke

AcT
Start date: December 10, 2019
Phase: Phase 3
Study type: Interventional

The proposed trial is a pragmatic, registry linked, prospective, randomized (1:1) controlled, open-label parallel group clinical trial with blinded endpoint assessment of 1600 patients to test if intravenous tenecteplase (0.25 mg/kg body weight, max dose 25 mg) is non-inferior to intravenous alteplase (0.9 mg/kg body weight) in patients with acute ischemic stroke otherwise eligible for intravenous thrombolysis as per standard care. All patients will have standard of care medical management on an acute stroke unit. There are no additional trial specific management recommendations. Patients will be followed for approximately 90-120 days.

NCT ID: NCT03887143 Completed - Clinical trials for Arterial Ischemic Stroke

National Retrospective Study Of Recanalization Treatments In Pediatric Arterial Ischemic Stroke

KID-CLOT
Start date: April 4, 2019
Phase:
Study type: Observational

The purpose of this study is to evaluate recanalization treatments use, safety and efficacy at the acute phase of arterial ischemic stroke in pediatric patients

NCT ID: NCT03884530 Completed - Ischemic Stroke Clinical Trials

Ticagrelol Versus Aspirin in Ischemic Stroke

Start date: May 1, 2019
Phase: Phase 3
Study type: Interventional

There is a debate whether ticagrelor is superior to aspirin in treating patients with ischemic stroke or not, most of the studies examine the effect of both drugs within 24 hours of acute stroke some find that there is no difference between ticagrelor and aspirin, others find that ticagrelor is superior to aspirin. At this study the investigators aim at evaluating the role of loading ticagrelor received within 9 hours of acute ischemic stroke in improving neurological outcome of stroke. And evaluating the risk of hemorrhagic and non- hemorrhagic complications associated with the use of ticagrelor180 ml oral loading dose within 9 hours acute ischemic stroke

NCT ID: NCT03884166 Recruiting - Stroke, Ischemic Clinical Trials

MUcociliary Clearance IN Stroke

MUCINS
Start date: June 30, 2021
Phase:
Study type: Observational

Stroke patients frequently suffer from stroke associated pneumonia. Pathophysiologically speaking, dysphagia and central nervous system (CNS)-injury induced immunosuppression largely contribute to the risk for pneumonia. In mouse models for stroke, the self-cleaning mechanisms of the lung are also affected by stroke, possibly further contributing to this risk. The investigators designed a pilot-study to examine the structural and functional integrity of the self-cleaning mechanisms of the lung in stroke patients.

NCT ID: NCT03884153 Recruiting - Stroke, Ischemic Clinical Trials

CASTRO-B - Study on CRP Apheresis in STROke Patients in Berlin

CASTRO-B
Start date: December 3, 2020
Phase: N/A
Study type: Interventional

This study explores the use of CRP level reduction in patients after suffering from acute ischemic stroke. Using selective CRP-apheresis, the investigators aim to reduce the secondary inflammatory tissue damage in the course of infarction maturation using infarction growth in MRI as the primary outcome as a surrogate.

NCT ID: NCT03876457 Completed - Clinical trials for Acute Ischemic Stroke

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

SELECT2
Start date: October 11, 2019
Phase: N/A
Study type: Interventional

SELECT 2 evaluates the efficacy and safety of endovascular thrombectomy compared to medical management alone in acute ischemic stroke patients due to a large vessel occlusion in the distal ICA and MCA M1 who have large core on either CT (ASPECTS: 3-5) or advanced perfusion imaging ([rCBF<30%] on CTP or [ADC<620] on MRI: ≥50cc) or both and are treated within 0-24 hours from last known well.

NCT ID: NCT03874702 Enrolling by invitation - Stroke Clinical Trials

Automated Diagnosis of Stroke in Computed Tomography With the Use of Artificial Intelligence

Start date: August 15, 2019
Phase:
Study type: Observational [Patient Registry]

The use of the systems of machine learning for the quantification, location and diagnosis of ischemic stroke in non-contrasted head computed tomography, is a method with high efficacy, accessible and susceptible for standardization, for the assistance in the clinical decision making in the absence of specialized health personnel for the attention of this disease.